CLINICAL STUDY OF IMIPENEM/CILASTATIN SODIUM PART II THE EFFECT OF IMIPENEM/CILASTATIN SODIUM ON PLATELET FUNCTION AND BLOOD COAGULATION

Recently, a tendency to bleed as a side effect of antibiotics has been given attention. We studied the effect of imipenem/cilastatin sodium (IPM/CS), a carbapenem antibiotic which belongs to a new class of beta-lactam agents, on platelet function and blood coagulation. The subjects were 11 patients...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 37; no. 7; pp. 896 - 902
Main Authors NAKAGAMI, KAZUKIYO, SUZUKI, HAJIME, NOGUCHI, EISEI, AKIZAWA, TAKANORI, TERADA, HIDEO
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1989
公益社団法人 日本化学療法学会
Subjects
Online AccessGet full text
ISSN0009-3165
1884-5894
DOI10.11250/chemotherapy1953.37.896

Cover

Abstract Recently, a tendency to bleed as a side effect of antibiotics has been given attention. We studied the effect of imipenem/cilastatin sodium (IPM/CS), a carbapenem antibiotic which belongs to a new class of beta-lactam agents, on platelet function and blood coagulation. The subjects were 11 patients with respiratory infections: 10 with pneumonia and 1 with pulmonary suppuration. IPM/CS was administered by i. v. drip at a dose of 1 g/day for 7 days, and the following parameters measured before and after treatment: platelet count, bleeding time, platelet adhesiveness, platelet aggregation, platelet ATP release, prothrombin time, active partial thromboplastin time, serum fibrinogen, fibrin degradation products, thrombo test and clotting factors II·VII·IV·V. There was no deterioration in the platelet function or blood coagulation tests after administrations of IPM/CS. We therefore concluded that IPM/CS is a safe antibiotic in regard to platelet function and blood coagulation.
AbstractList Recently, a tendency to bleed as a side effect of antibiotics has been given attention. We studied the effect of imipenem/cilastatin sodium (IPM/CS), a carbapenem antibiotic which belongs to a new class of beta-lactam agents, on platelet function and blood coagulation. The subjects were 11 patients with respiratory infections: 10 with pneumonia and 1 with pulmonary suppuration. IPM/CS was administered by i. v. drip at a dose of 1 g/day for 7 days, and the following parameters measured before and after treatment: platelet count, bleeding time, platelet adhesiveness, platelet aggregation, platelet ATP release, prothrombin time, active partial thromboplastin time, serum fibrinogen, fibrin degradation products, thrombo test and clotting factors II·VII·IV·V. There was no deterioration in the platelet function or blood coagulation tests after administrations of IPM/CS. We therefore concluded that IPM/CS is a safe antibiotic in regard to platelet function and blood coagulation.
Recently, a tendency to bleed as a side effect of antibiotics has been given attention.We studied the effect of imipenem/cilastatin sodium (IPM/CS), a carbapenem antibiotic which belongs to a new class of beta-lactam agents, on platelet function and blood coagulation.The subjects were 11 patients with respiratory infections: 10 with pneumonia and 1 with pulmonary suppuration.IPM/CS was administered by i. v. drip at a dose of 1 g/day for 7 days, and the following parameters measured before and after treatment: platelet count, bleeding time, platelet adhesiveness, platelet aggregation, platelet ATP release, prothrombin time, active partial thromboplastin time, serum fibrinogen, fibrin degradation products, thrombo test and clotting factors II·VII·IV·V. There was no deterioration in the platelet function or blood coagulation tests after administrations of IPM/CS.We therefore concluded that IPM/CS is a safe antibiotic in regard to platelet function and blood coagulation. 最近抗生物質投与に伴う副作用として出血傾向が注目されている。そこで我々は, 新しく開発されたカルバペネム系抗生物質イミペネム (IPM) と同剤の尿中回収率を高めるシラスタチンナトリウム (CS) との合剤であるチェナム® (以下IPM/CS) の, 血小板機能・出血凝固機能に対する影響について検討した。対象は肺炎10例, 肺化膿症1例の計11例の呼吸器感染症である。IPM/CSは原則として1日IPM量として1gを7日間点滴静注し, その前後で血小板数, 出血時間, 血小板粘着能, 血小板凝集能, 血小板ATP放出能, プロトロンビン時間, 活性部分トロンボプラスチン時間, 血漿フィブリノーゲン, フィブリン分解産物, トロンボテスト, 第II・VII-IX・X凝固因子を測定した。各検査結果がIPM/CS投与後で増悪した症例は認められず, このことよりIPM/CSは, 1日1g7日間程度の投与では血小板機能, 出血凝固機能に影響を与えることの無い, 安全な抗生物質であると考えられた。
Author AKIZAWA, TAKANORI
NOGUCHI, EISEI
TERADA, HIDEO
NAKAGAMI, KAZUKIYO
SUZUKI, HAJIME
Author_FL 野口 英世
中神 和清
秋澤 孝則
鈴木 一
寺田 秀夫
Author_FL_xml – sequence: 1
  fullname: 秋澤 孝則
– sequence: 2
  fullname: 中神 和清
– sequence: 3
  fullname: 鈴木 一
– sequence: 4
  fullname: 野口 英世
– sequence: 5
  fullname: 寺田 秀夫
Author_xml – sequence: 1
  fullname: NAKAGAMI, KAZUKIYO
  organization: Division of Respiratory Diseases, School of Medicine, Showa University, Fujigaoka Hospital
– sequence: 1
  fullname: SUZUKI, HAJIME
  organization: Division of Respiratory Diseases, School of Medicine, Showa University, Fujigaoka Hospital
– sequence: 1
  fullname: NOGUCHI, EISEI
  organization: Division of Respiratory Diseases, School of Medicine, Showa University, Fujigaoka Hospital
– sequence: 1
  fullname: AKIZAWA, TAKANORI
  organization: Division of Respiratory Diseases, School of Medicine, Showa University, Fujigaoka Hospital
– sequence: 1
  fullname: TERADA, HIDEO
  organization: Division of Hematology, School of Medicine, Showa University, Fujigaoka Hospital
BackLink https://cir.nii.ac.jp/crid/1390001206278904448$$DView record in CiNii
BookMark eNpdkMtuwjAURK2KSqWUf_Ci24Dt61eWUYDWUniohEVXlmPcEgQBJdnw94TSRdXNXI10NLozz6hXnaqAEKZkRCkTZOx34Xhqd6F25wuNBYxAjXQsH1Cfas0joWPeQ31CSBwBleIJDZumLAihlEimWR_xNDMLkyYZXuebySdezrCZm9V0MZ2PU5Ml6zzJzQKvlxOzmeNV8pFjY17Q45c7NGH4ewdoM5vm6XuULd9uWdGeStlGBacysDhoFQoipNO8kA7kFrxTGoAo5jsjfJBcUM4Lz5nzAKDAObblGgbo9Z5blaX15U0pxF0byrr3lY4J5z9Ydsf2Teu-gz3X5dHVF-vqtvSHYP-PZEFZdZduqz-Yq22o4Ar72WFp
ContentType Journal Article
Copyright Japanese Society of Chemotherapy
Copyright_xml – notice: Japanese Society of Chemotherapy
DBID RYH
DOI 10.11250/chemotherapy1953.37.896
DatabaseName CiNii Complete
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate Imipenem/cilastatin sodiumの血小板機能・出血凝固機能におよぼす影響
THE EFFECT OF IMIPENEM/CILASTATIN SODIUM ON PLATELET FUNCTION AND BLOOD COAGULATION
DocumentTitle_FL Imipenem/cilastatin sodiumの血小板機能・出血凝固機能におよぼす影響
EISSN 1884-5894
EndPage 902
ExternalDocumentID 130004072702
article_chemotherapy1953_37_7_37_7_896_article_char_en
GroupedDBID 53G
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
DIK
JSF
JSH
KQ8
RJT
RZJ
ZOHVM
RYH
ID FETCH-LOGICAL-j166t-b416e29e87eb056a84b6a36d3ca7833072c6d35ce645144bc42ac33373aa2d483
ISSN 0009-3165
IngestDate Thu Jun 26 23:41:49 EDT 2025
Wed Sep 03 06:09:55 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Issue 7
Language English
Japanese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-j166t-b416e29e87eb056a84b6a36d3ca7833072c6d35ce645144bc42ac33373aa2d483
OpenAccessLink https://www.jstage.jst.go.jp/article/chemotherapy1953/37/7/37_7_896/_article/-char/en
PageCount 7
ParticipantIDs nii_cinii_1390001206278904448
jstage_primary_article_chemotherapy1953_37_7_37_7_896_article_char_en
PublicationCentury 1900
PublicationDate 1989-00-00
PublicationDateYYYYMMDD 1989-01-01
PublicationDate_xml – year: 1989
  text: 1989-00-00
PublicationDecade 1980
PublicationTitle CHEMOTHERAPY
PublicationTitleAlternate Chemother.
PublicationTitle_FL CHEMOTHERAPY
Chemother
PublicationYear 1989
Publisher Japanese Society of Chemotherapy
公益社団法人 日本化学療法学会
Publisher_xml – name: Japanese Society of Chemotherapy
– name: 公益社団法人 日本化学療法学会
References 6) SATTLER F R, WEITEKAMP M R, SAYEGH A, BALLARD J O: Impaired hemostasis caused by beta-lactam antibiotics. Am. J. Surg. 155: 30-39, 1988
9) 竹田治土, 橋本正人, 田辺達三: Cefotaxime,(Claforanr®) 投与後の凝固線溶系の変動. 外科診療26: 1077-1082, 1984
16) NEU H C: The new beta-lactamasestaoie cephalosporins. Ann. Intern. Med. 97: 408-419, 1982
1) 重野芳輝, 斉藤厚: セフェム系抗生物質と出血性素因. 医薬ジャーナル20: 663-669, 1984
13) 丸山宗治, 水島豊, 本敦文, 山下直宏, 杉山英二, 星野清, 横山彰仁, 矢野三郎: セフェム系抗生物質が原因として疑われたびまん性肺出血の1例. 日胸疾会誌24: 316-319, 1986
8) BROWN C H, NATELSON E A, BRADSHAW M W, ALFREY C P, WILLIAMS T W: Study on the effects of ticarcillin on blood coagulation and platelet function. Antimicron. Agent. Chemother. 7: 652-657, 1975
5) NEU H C: Adverse effects of new cephalosporins. Ann. Intern. Med. 98: 415-416, 1983
4) 島田馨: β-ラクタム剤使用時の出血傾向. 臨床検査29: 1117-1118, 1985
11) 伊藤邦彦, 早崎源基, 野田克己, 小池茂文, 松本興治: 血液凝固血小板, 線溶系に対するcefmenoxime (CMX) の影響についての検討. Chemotherapy 34: 511-521, 1986
2) 内田清久, 石神豊一: 血液凝固異常. β-ラクタム系薬. 南江堂: 124-132, 1987
12) 大塚薫: Cefotaximeの血液凝固系 (特にビタミンK依存凝固因子) に及ぼす影響に対する検討. 診療と新薬23: 2255-2259, 1986
7) BANG N U, TESSLER S S, HEIDENREICH R O, MARKS C A and MATTLER L E: Effect of moxalactam on blood coagulation and platelet function. Rev. Infect. Dis. 4: S 546-S 554, 1982
15) 寺田秀夫: 血小板凝集能. 臨床病理臨時増刊特集第71号 (2) 血小板編: 151-156, 1687
17) BIRNBAUM J, KAHAN F M, KROOP H, MACDONALD J: Carbapenems, A New Class of Beta-Lactam Antibiotics. Discovery and development of Imipenem/Cilastatin. Am. J. Med. 78 (S-6 A): 3-21, 1985
10) 小池和夫, 小林裕, 村松学, 真弓克彦, 北原克之, 藤沢弘芳, 松岡松三: 抗生物質投与後にみられた出血傾向の8例. 診療と新薬22: 1365-1378, 1985
14) 伊藤邦彦, 和泉孝治, 高木博, 近藤英明, 玉舎輝彦, 早崎源基: 血液凝固系に対するcefotaximeの影響についての検討. Chemotherapy 36: 1-9, 1988
19) 山本學: 血小板機能検査とその臨床的意義. 臨床成人病13: 2385-2390, 1983
20) 寺田秀夫: 組織因子, 第VII因子. 臨床病理臨時増刊特集第71号 (1) 血液凝固編: 167-172, 1987
18) 池田康夫: 血小板機能の検査. 診断と治療3: 657-661, 1987
3) 古泉秀夫: 抗生物質の副作用プロトロンビン時間延長. THPA35: 196-201, 1986
References_xml – reference: 18) 池田康夫: 血小板機能の検査. 診断と治療3: 657-661, 1987
– reference: 5) NEU H C: Adverse effects of new cephalosporins. Ann. Intern. Med. 98: 415-416, 1983
– reference: 9) 竹田治土, 橋本正人, 田辺達三: Cefotaxime,(Claforanr®) 投与後の凝固線溶系の変動. 外科診療26: 1077-1082, 1984
– reference: 11) 伊藤邦彦, 早崎源基, 野田克己, 小池茂文, 松本興治: 血液凝固血小板, 線溶系に対するcefmenoxime (CMX) の影響についての検討. Chemotherapy 34: 511-521, 1986
– reference: 17) BIRNBAUM J, KAHAN F M, KROOP H, MACDONALD J: Carbapenems, A New Class of Beta-Lactam Antibiotics. Discovery and development of Imipenem/Cilastatin. Am. J. Med. 78 (S-6 A): 3-21, 1985
– reference: 2) 内田清久, 石神豊一: 血液凝固異常. β-ラクタム系薬. 南江堂: 124-132, 1987
– reference: 16) NEU H C: The new beta-lactamasestaoie cephalosporins. Ann. Intern. Med. 97: 408-419, 1982
– reference: 12) 大塚薫: Cefotaximeの血液凝固系 (特にビタミンK依存凝固因子) に及ぼす影響に対する検討. 診療と新薬23: 2255-2259, 1986
– reference: 15) 寺田秀夫: 血小板凝集能. 臨床病理臨時増刊特集第71号 (2) 血小板編: 151-156, 1687
– reference: 4) 島田馨: β-ラクタム剤使用時の出血傾向. 臨床検査29: 1117-1118, 1985
– reference: 20) 寺田秀夫: 組織因子, 第VII因子. 臨床病理臨時増刊特集第71号 (1) 血液凝固編: 167-172, 1987
– reference: 1) 重野芳輝, 斉藤厚: セフェム系抗生物質と出血性素因. 医薬ジャーナル20: 663-669, 1984
– reference: 7) BANG N U, TESSLER S S, HEIDENREICH R O, MARKS C A and MATTLER L E: Effect of moxalactam on blood coagulation and platelet function. Rev. Infect. Dis. 4: S 546-S 554, 1982
– reference: 8) BROWN C H, NATELSON E A, BRADSHAW M W, ALFREY C P, WILLIAMS T W: Study on the effects of ticarcillin on blood coagulation and platelet function. Antimicron. Agent. Chemother. 7: 652-657, 1975
– reference: 6) SATTLER F R, WEITEKAMP M R, SAYEGH A, BALLARD J O: Impaired hemostasis caused by beta-lactam antibiotics. Am. J. Surg. 155: 30-39, 1988
– reference: 10) 小池和夫, 小林裕, 村松学, 真弓克彦, 北原克之, 藤沢弘芳, 松岡松三: 抗生物質投与後にみられた出血傾向の8例. 診療と新薬22: 1365-1378, 1985
– reference: 13) 丸山宗治, 水島豊, 本敦文, 山下直宏, 杉山英二, 星野清, 横山彰仁, 矢野三郎: セフェム系抗生物質が原因として疑われたびまん性肺出血の1例. 日胸疾会誌24: 316-319, 1986
– reference: 3) 古泉秀夫: 抗生物質の副作用プロトロンビン時間延長. THPA35: 196-201, 1986
– reference: 14) 伊藤邦彦, 和泉孝治, 高木博, 近藤英明, 玉舎輝彦, 早崎源基: 血液凝固系に対するcefotaximeの影響についての検討. Chemotherapy 36: 1-9, 1988
– reference: 19) 山本學: 血小板機能検査とその臨床的意義. 臨床成人病13: 2385-2390, 1983
SSID ssib001106282
ssj0000626693
ssib058492509
ssib005879733
ssib008506721
Score 1.201225
Snippet Recently, a tendency to bleed as a side effect of antibiotics has been given attention. We studied the effect of imipenem/cilastatin sodium (IPM/CS), a...
Recently, a tendency to bleed as a side effect of antibiotics has been given attention.We studied the effect of imipenem/cilastatin sodium (IPM/CS), a...
SourceID nii
jstage
SourceType Publisher
StartPage 896
SubjectTerms IPM/CS
出血傾向
出血凝固機能
血小板機能
Subtitle THE EFFECT OF IMIPENEM/CILASTATIN SODIUM ON PLATELET FUNCTION AND BLOOD COAGULATION
Title CLINICAL STUDY OF IMIPENEM/CILASTATIN SODIUM PART II
URI https://www.jstage.jst.go.jp/article/chemotherapy1953/37/7/37_7_896/_article/-char/en
https://cir.nii.ac.jp/crid/1390001206278904448
Volume 37
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX CHEMOTHERAPY, 1989/07/25, Vol.37(7), pp.896-902
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pb9MwFLa6ceGCQIAYYygHblW6pXb942h12ep1Sao1EdsuUeK4UitR0NQd4O_gD-Y5TtMMDQkmLlaTJk7s9_re59f3PiP0qRTaLE4Wxl8QoX0CAMQvTcl9EpRaB7gynNl65yimk4xcXI-ue72fnayl-0050D8erSt5ilThHMjVVsn-g2TbTuEEfAb5QgsShvavZDy-VLHjMwBcd2MTeMAUzcI4jCztrbqU81SmKu7Pk1OVRf0ZgNe-Ul08ahkRknQSXslZi2ljOZXnMlK1DZC32VTdJG0gJrPHtb-SFypqyxji5DwbT-ovQjUP21CsnKpb-Vm69MCpjJMrtYsz2ESqnfUHr213w2zzSOs8EfOlqRD7_sC8CjDqbvOHgXEWlXPij7jbyXhrch3PS6NarGM_uaAdVyzqYuxHrDzgNphH3XkJ-2_gALNB28EDDu1GQvnvd-SY5cw1cGO-u6y4A_3aQ8-GjAU2UfRUTXcgM7B1px2SM84E64BmywHYIZ0DhCfgfUUb-YO7KRXtFn92vrYpZnDd8R9GBQhpBesFSwSxt14uOyAofYleNKsXT7oRvEK9VfEaka0aerUaesmZt1XD450Sek4JPauEnlJvUHYWpuOJ32zG4a8CSjd-CcjdDAX8dg2MiRaclLTAtMK6YByDpxhqOBhpQwlgcFJqMiw0xpjhohhWhOO3aH_9dW3eIY-NygozcB5VwO2KHbqqOOaUg7PB1Ul1gEI31PybY1zJnya_A3QEM5XrpW1hpVNHXS0tNxeWJZG__0_POUTPXeahDcx9QPubu3tzBFB1U36sNecXI_KCSA
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CLINICAL+STUDY+OF+IMIPENEM%2FCILASTATIN+SODIUM+PART+II&rft.jtitle=CHEMOTHERAPY&rft.au=NAKAGAMI%2C+KAZUKIYO&rft.au=SUZUKI%2C+HAJIME&rft.au=NOGUCHI%2C+EISEI&rft.au=AKIZAWA%2C+TAKANORI&rft.date=1989&rft.pub=Japanese+Society+of+Chemotherapy&rft.issn=0009-3165&rft.eissn=1884-5894&rft.volume=37&rft.issue=7&rft.spage=896&rft.epage=902&rft_id=info:doi/10.11250%2Fchemotherapy1953.37.896&rft.externalDocID=article_chemotherapy1953_37_7_37_7_896_article_char_en
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-3165&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-3165&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-3165&client=summon